Is a complete RNAZ research report available?

No complete published report is available for TransCode Therapeutics, Inc. (RNAZ) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · USD

$5.93

-1.32 (-18.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first RNAZ analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	5.6M
Net income (ttm)	-43.7M
EPS (ttm)	-$49.9
Shares out	950.3K
Volume	24,546
Beta	1.24

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -43.7M
EPS (ttm): -$49.9
Market cap: 5.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All RNAZ indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001829635
Company name	TransCode Therapeutics, Inc.
Country	United States
Country code	US
Cusip	89357L501
Employees	12
Employees Change	5%
Employees Change Percent	71.43
Enterprise value	$-7.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-07-09
Isin	US89357L5012
Last refreshed	2026-07-25
Market cap	$5.6M
Market cap category	Nano-Cap
Price	$5.93
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.59
Sic	2834
Symbol	RNAZ
Website	https://www.transcodetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-782%
FCF yield	-383.05%
P/B ratio	5.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-43.7M
Net Income Growth Years	0%
Profit Per Employee	$-3.6M
ROA	-17.13
Roa5y	-93.96
ROCE	-28.04
ROE	-52.14
ROIC	-18.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-47.41%
Cagr3y	-95.93%
Cagr5y	-92.51%
EPS Growth Quarters	5
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$157.2M
Cash	$12.8M
Current Assets	$16.7M
Current Liabilities	$5.4M
Debt	$0
Equity	$144.5M
Interest Coverage	-6,546.3
Liabilities	$12.6M
Long Term Assets	$140.4M
Long Term Liabilities	$7.3M
Net Cash	$12.8M
Net Cash By Market Cap	$230
Net Cash Growth	10.95%
Net Debt Equity	$-0.09
Tangible Book Value	$-138.8M
Tangible Book Value Per Share	$-151
WACC	11.05

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.11
Net Working Capital	$-1.5M
Quick ratio	2.39
Working Capital	$11.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1,515.08%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-47.38%
200-day SMA	8.76
3Y total return	-99.99%
50-day SMA	6.42
50-day SMA vs 200-day SMA	50under200
5Y total return	-100%
All Time High	5,174,453
All Time High Change	-100%
All Time High Date	2021-07-09
All Time Low	3.82
All Time Low Change	55.24%
All Time Low Date	2026-06-03
ATR	1.01
Beta	1.24
Beta1y	0.15
Beta2y	2.77
Ch YTD	-13.18
High	6.69
High52	20.99
High52 Date	2025-10-08
High52ch	-71.75%
Low	5.85
Low52	3.82
Low52 Date	2026-06-03
Low52ch	55.24%
Ma50ch	-7.63%
Premarket Change Percent	-5.38
Premarket Price	$6.86
Premarket Volume	824
Price vs 200-day SMA	-32.27%
RSI	40.33
RSI Monthly	22.65
RSI Weekly	33.77
Sharpe ratio	-0.06x
Sortino ratio	-0.03
Total Return	-1,515.08%
Tr YTD	-13.18
Tr1m	22.14%
Tr1w	-29.66%
Tr3m	-31.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-23.4M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	865,764%
Float Percent	91.1%
Shares Insiders	0.13%
Shares Institutions	7.61%
Shares Out	950,302
Shares Qo Q	0.43%
Shares Yo Y	1,515.08%
Short Float	6.1%
Short Ratio	0.37
Short Shares	5.56

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-21.7M
Average Volume	29,938.8x
Bv Per Share	1.36
CAPEX	$-6,660
Ch1m	22.14
Ch1w	-29.66
Ch1y	-47.38
Ch3m	-31.6
Ch3y	-99.99
Ch5y	-100
Ch6m	-39.92
Change	-18.21%
Change From Open	-8.06
Close	7.25
Days Gap	-11.03
Depreciation Amortization	86,939
Dollar Volume	145,557.8
Earnings Date	2026-05-15
Earnings Time	amc
EBIT	$-42.6M
EBITDA	$-42.5M
EPS	$-49.89
F Score	1
FCF	$-21.4M
FCF EV Yield	295.33x
FCF Per Share	$-22.52
Financing CF	22,668,325
Fiscal Year End	December
Founded	2,016
Goodwill	25,744,143
Income Tax	$457,377
Investing CF	-4,436
Ipr	47
Iprfo	-100
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Date	2025-05-15
Last Split Type	Reverse
Last10k Filing Date	2026-04-15
Ma150	8.05
Ma150ch	-26.33%
Ma20	7.63
Ma20ch	-22.27%
Net CF	1,266,300
Next Earnings Date	2026-11-13
Open	6.45
Optionable	No
Position In Range	9.52
Post Close	5.93
Postmarket Change Percent	0.84
Postmarket Price	$5.98
Ppne	346,745
Pre Close	7.25
Price Date	2026-07-24
Relative Volume	0.82x
Share Based Comp	327,699
Tr6m	-39.92%
Us State	Massachusetts
Volume	24,546

TransCode Therapeutics, Inc. (RNAZ)

Coverage state: Market snapshot only — no published research

Generate the first RNAZ analysis

Price

Financial snapshot

Fair-value bridge

Latest news · RNAZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RNAZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on RNAZ

Frequently asked questions